title: Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists.
abstract: OBJECTIVE
  This study is based on promising results using the ratio of free/ total (F/T) prostatic-specific antigen (PSA) for discrimination between benign prostatic hypertrophy and prostate cancer. We tried to determine the value of F/T PSA in different clinical situations at a certain time point during follow-up of luteinizing-hormone-releasing hormone (LH-RH) agonist treatment and to correlate it to T-PSA.
  
  
  METHODS
  182 patients followed-up for different periods in the last 3 years were routinely monitored for serum T-PSA. During the last 11 months, F-PSA was also measured together with T-PSA, and the ratio of F/T PSA was calculated. In 26 patients, the ratio of F/T PSA was monitored sequentially in several samples.
  
  
  RESULTS
  Although 5 patterns of clinical response to LH-RH agonists were identified according to previous T-PSA, the F/T ratio could significantly (p < 0.05) discriminate between patients responding to treatment in contrast to patients escaping, fluctuating or not responding to hormonal ablation. Those patients responding to hormones showed a higher F/T PSA ratio (36.5 +/- 33.1%) compared to the nonresponding group (12.0 +/- 10.1%).
  
  
  CONCLUSIONS
  During individual follow-ups, the pattern of response to LH-RH treatment is reflected by the F/T PSA ratio: while successful treatment causes an F/T PSA increase, relapse is accompanied by a decrease in this ratio. However, the changes in the F/T PSA ratio did not precede the indicative changes in T-PSA. It seems that increased values of F/T PSA ratios are intrinsic features of 'benign' prostatic disease, and the molecular events resulting in different PSA molecules in various clinical situations have to be elucidated.
authors.affiliation: Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: M
authors.initials: M
authors.lastname: Barak
authors.forename: Y
authors.initials: Y
authors.lastname: Mecz
authors.forename: R
authors.initials: R
authors.lastname: Rubinov
authors.forename: A
authors.initials: A
authors.lastname: Lurie
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists* / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D007987:Gonadotropin-Releasing Hormone; D017430:Prostate-Specific Antigen